MaxCyte Investor Presentation Deck

Value Creation from SPLs ℗ tit Licensing deals include significant development milestones and high-value participation in future commercial success of partners Potential value of pre-commercial (clinical development) milestones from SPLs:~$2B Sales-based payments upon partner's product commercialization Recurring revenues from lease of instruments and sales of single-use disposables that grow with program success Milestone revenue is MaxCyte's highest growth revenue stream **Casebia/CRISPR's SPL partnership (signed in 2017) included the rights to use MaxCyte's technology in the development of exa- cel (formerly known as CTX001). As announced in the press release on September 28th, 2022, Vertex has signed an SPL agreement with MaxCyte - Vertex has obtained the clinical and commercial rights to use MaxCyte's technology for the development of exa-cel (formerly known as CTX001). CASEBIA THERAPEUTICS 2017 8 Cumulative Potential Pre-CML Milestones Potential Value of Pre-Commercial Milestones:~$2B USD PRECISION BIOSCIENCES CRISPRI THERAPEUTICS 2018 KSQ VOR BIOPHARMA editas MEDICINE Beam THERAPEUTICS Kite AGILEADCY 2019 invios INNOVATIVE IMMUNO-ONCOLOGY CARIBOU BIOSCIENCES Allogene 2020 nkarta THERAPEUTICS CO celularity MYELCID Sana VERTEX Biotechnology 2021 curomys ** M MaxCyte LG Chem INTIMA BIOSCIENCE 2022 Graph is provided for illustrative purposes only. prime medicine__ VITTORIA biotherapeutics Lyell Immunopharma WALKING FISH THERAPEUTICS catamaranBIO 2023 LION TCR WE FUNT VIRUSES 2024 © 2023 MaxCyte, Inc. All Rights Reserved

View entire presentation